NCT07437586 Topical GHK-Cu Gel for Acute Skin Wound Healing
| NCT ID | NCT07437586 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Hudson Biotech |
| Condition | Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-02-02 |
| Primary Completion | 2027-02-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 60 participants in total. It began in 2026-02-02 with a primary completion date of 2027-02-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will evaluate whether a topical gel containing GHK-Cu (a copper(II)-peptide complex) can safely speed up healing of small, standardized skin wounds in healthy adults compared with a matching vehicle gel. Participants will receive two small punch-biopsy wounds on the upper arm; each wound will be randomly assigned to receive GHK-Cu gel or vehicle gel under identical dressings. Wounds will be photographed and assessed over 3 weeks, with a follow-up visit to evaluate scar quality.
Eligibility Criteria
Inclusion Criteria: * Age 18 to 55 years at screening. * Healthy adult as determined by medical history and limited physical examination. * Body mass index (BMI) 18.0 to 30.0 kg/m². * Willing and able to comply with study visits and daily product application for 14 days. * Willing to avoid applying non-study topical products (including medicated creams, retinoids, acids) to the wound area during the study period. * For participants of childbearing potential: negative pregnancy test at screening and agreement to use effective contraception through Day 21. Exclusion Criteria: * Known allergy or sensitivity to copper, peptides, gel excipients, adhesives, or dressings used in the study. * History of abnormal wound healing, hypertrophic scarring, or keloid formation. * Clinically significant dermatologic disease near the intended wound site (e.g., eczema, psoriasis, active infection). * Diabetes mellitus, peripheral vascular disease, immunodeficiency, or other condition that may impair wound healing (investigator judgment). * Use of systemic corticosteroids, immunosuppressants, or cytotoxic medications within 30 days prior to Day 0. * Current smoker or nicotine use (including vaping) within the past 3 months. * Pregnant or breastfeeding. * Participation in another interventional clinical study within 30 days prior to screening. * Any condition that, in the investigator's opinion, would make participation unsafe or could interfere with study assessments.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07437586 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07437586 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07437586 currently recruiting?
Yes, NCT07437586 is actively recruiting participants. Contact the research team at Seni-Lu@beijing-biotech.com for enrollment information.
Where is the NCT07437586 trial being conducted?
This trial is being conducted at Shenzhen, China.
Who is sponsoring the NCT07437586 clinical trial?
NCT07437586 is sponsored by Hudson Biotech. The trial plans to enroll 60 participants.